When facing a complex genetic condition that affects the brain and nervous system, understanding all available treatment approaches becomes essential for patients and their families—especially when early intervention can make a significant difference in outcomes and quality of life.

How Treatment Helps Manage This Complex Condition

The main goals of treating adrenoleukodystrophy are centered on slowing down disease progression, managing symptoms, and improving the overall quality of life for those affected. Treatment strategies must be carefully tailored to each person’s specific situation, taking into account which form of the disease they have, how far it has progressed, and their individual health characteristics. The approach differs significantly between childhood cerebral forms, which can progress rapidly, and adult-onset forms, which typically advance more slowly over time.^[1]

Medical societies and specialists have established standard treatments that have shown benefits for certain aspects of the disease, particularly for managing adrenal gland problems. At the same time, researchers around the world are actively investigating new therapeutic approaches through clinical trials, seeking better ways to halt or reverse the damage caused by this condition. These experimental treatments represent hope for patients who currently have limited options, particularly those with forms of the disease that do not respond well to existing therapies.^[2]

The timing of treatment is critically important. For the childhood cerebral form, interventions work best when started during the earliest stages of brain involvement, before significant symptoms develop. This narrow window of opportunity makes regular monitoring and early detection through newborn screening programs increasingly vital. Many families face difficult decisions about pursuing aggressive treatments that carry their own risks, balanced against the potential to preserve brain function and extend life.^[12]

Standard Treatment Approaches

The most established and crucial treatment for all patients with adrenoleukodystrophy involves managing adrenal insufficiency, a condition where the adrenal glands fail to produce enough hormones. This aspect of treatment is well-understood and highly effective. Patients receive hormone replacement therapy with steroids to replace what their adrenal glands cannot produce naturally. This medication must be taken for life, and dosages need to be increased during times of illness or physical stress to prevent life-threatening adrenal crises. Treating adrenal insufficiency is lifesaving and allows patients to maintain stable hormone levels.^[4]

For boys diagnosed with early-stage childhood cerebral adrenoleukodystrophy, allogeneic hematopoietic stem cell transplantation represents the only currently approved treatment that can stabilize disease progression. This procedure involves transplanting healthy stem cells from a donor—either from bone marrow or umbilical cord blood—into the patient after their own immune system has been eliminated through high-dose chemotherapy or radiation. The goal is to provide the patient’s body with cells that can produce the functioning protein that is missing in adrenoleukodystrophy. When these donor cells successfully engraft and reach the brain, they can halt or even reverse some of the brain damage.^[8]

Stem cell transplantation works best when performed early in the disease course, specifically when brain lesions first appear on magnetic resonance imaging (MRI) but before significant symptoms develop. Patients with lower disease severity scores—typically a Loes score below 9, which measures the extent of brain damage—generally have better outcomes. Studies show that boys with early disease who receive transplants have survival rates around 94% at two years and maintain better neurological function compared to those transplanted at later stages.^[12]

However, this treatment carries substantial risks that families must carefully consider. The mortality rate from the transplant procedure itself ranges from 8% to 12% within the first 100 days. Other serious complications include graft failure, where the transplanted cells do not successfully take hold in the patient’s body, which occurs in 5% to 18% of cases. Additionally, graft-versus-host disease—where the donor cells attack the patient’s own tissues—develops in a significant number of patients, causing both acute symptoms and long-term health problems. The immunosuppression required to prevent rejection also leaves patients vulnerable to serious infections for months or years after the procedure.^[12]

Another challenge with stem cell transplantation is that disease progression typically continues for six to eighteen months after the procedure, even in successful cases. This means that children emerge from treatment with more advanced brain damage than they had going into it. The hope is that the transplant will then halt further decline, but this represents a significant trade-off that families must accept. Furthermore, finding a well-matched donor can be difficult, and outcomes are generally better when cells come from a matched sibling donor, which is only available for less than 30% of patients.^[11]

A dietary therapy known as Lorenzo’s oil has been used since the 1980s as a treatment approach. This mixture combines specific fatty acids extracted from olive oil and rapeseed oil. The oil works by reducing levels of very-long-chain fatty acids in the bloodstream, which are known to accumulate in people with adrenoleukodystrophy and contribute to disease progression. Lorenzo’s oil is taken orally alongside a low-fat diet.^[5]

Research indicates that Lorenzo’s oil may be effective in preventing or delaying the onset of symptoms in boys who have been diagnosed with the genetic mutation but have not yet developed any brain involvement. A study following boys who took Lorenzo’s oil found that many remained symptom-free for years, suggesting the oil might offer protection during the asymptomatic phase. However, Lorenzo’s oil has not proven effective in treating boys who already have active cerebral disease with symptoms. It does not reverse existing brain damage or significantly slow progression once neurological symptoms have begun. The oil also does not prevent or treat adrenal insufficiency, so hormone replacement remains necessary.^[11]

Attempts to use immunosuppressive and immunomodulatory drugs to control the inflammatory brain damage seen in cerebral adrenoleukodystrophy have unfortunately failed to show benefits in clinical trials. These medications, designed to reduce the immune system’s attack on the myelin sheath around nerve cells, have not been able to prevent disease progression.^[13]

For adult men with adrenomyeloneuropathy, the slowly progressive form affecting the spinal cord and peripheral nerves, treatment options remain limited. Stem cell transplantation is generally not performed in adults because the risks are considered too high relative to potential benefits, given the slower disease course. Currently, adults receive supportive care to manage symptoms, including physical therapy to maintain mobility, medications for pain and muscle stiffness, and assistance with bladder and bowel problems as they develop. Research continues to search for therapies that might slow progression or improve function in this patient population.^[1]

Promising Treatments Being Tested in Clinical Trials

One of the most significant advances in experimental treatment involves gene therapy specifically designed for cerebral adrenoleukodystrophy. This innovative approach removes some of the patient’s own hematopoietic stem cells—cells that can develop into various blood and immune cells—and modifies them in the laboratory by inserting a functioning copy of the ABCD1 gene. This gene is the one that is defective in adrenoleukodystrophy and normally produces a protein necessary for breaking down very-long-chain fatty acids. After the genetic modification, these corrected cells are infused back into the patient.^[2]

The gene therapy works by providing the patient’s body with cells that can produce the missing protein. As these modified cells circulate and some reach the brain, they begin expressing the functional ABCD1 protein, which helps stop disease progression. An important advantage of this approach compared to transplantation from donors is that it uses the patient’s own cells, eliminating the risk of graft-versus-host disease and reducing the challenges of finding a matched donor. The therapy has now been approved and marketed under the name SKYSONA for treatment of early cerebral adrenoleukodystrophy.^[2]

Clinical trials have demonstrated that gene therapy can halt the progression of brain damage when administered during the early stages of cerebral involvement. Boys who received this treatment showed stabilization of neurological function, with many maintaining their ability to walk, communicate, and perform daily activities. Long-term follow-up of patients treated as early as 2013 shows some individuals have no detectable disease activity years after receiving gene therapy. Like conventional stem cell transplantation, gene therapy requires preparatory chemotherapy to make room in the bone marrow for the modified cells to engraft, which carries its own risks and side effects.^[2]

Researchers are exploring pharmacological approaches to increase expression of ABCD2, a gene closely related to ABCD1. The ABCD2 gene produces a protein with similar functions to the defective protein in adrenoleukodystrophy, and studies suggest that increasing ABCD2 expression might partially compensate for the loss of ABCD1 function. This strategy represents a form of pharmacological gene therapy, using medications to boost the body’s natural compensatory mechanisms rather than directly replacing the defective gene. Early laboratory studies have shown promise, though this approach remains experimental and requires further testing in human patients.^[13]

Another experimental avenue involves the use of antioxidant therapies. Research has revealed that the accumulation of very-long-chain fatty acids creates oxidative stress in cells, leading to damage of cellular components and contributing to disease progression. Antioxidant compounds might protect cells from this oxidative damage. Various antioxidant molecules are being studied in laboratory models to determine whether they can slow the deterioration of nerve cells and myelin. While this approach addresses one of the mechanisms by which the disease causes harm, clinical trials in patients have not yet demonstrated clear benefits.^[13]

Histone deacetylase inhibitors represent another class of experimental drugs being investigated for adrenoleukodystrophy. These medications, which include compounds like 4-phenylbutyrate and valproic acid, work by altering how genes are expressed in cells without changing the actual genetic code. Histone deacetylase inhibitors can increase expression of the ABCD2 gene, potentially providing some compensation for the defective ABCD1 gene. Valproic acid is already used clinically for other conditions such as epilepsy and mood disorders, which means its safety profile is well-understood. Studies are examining whether these medications might offer therapeutic benefits for adrenoleukodystrophy patients, particularly those forms of the disease for which stem cell transplantation is not appropriate.^[13]

A medication called lovastatin, part of the statin family of drugs commonly used to lower cholesterol, was investigated based on the theory that it might help normalize very-long-chain fatty acid levels through its effects on fat metabolism. However, clinical trials testing lovastatin in adrenoleukodystrophy patients did not show it to be effective in reducing these fatty acids or slowing disease progression. This demonstrates that not all theoretically promising approaches prove successful when tested in actual patients, highlighting the importance of rigorous clinical trials.^[13]

Clinical trials for adrenoleukodystrophy treatments typically progress through multiple phases. Phase I trials focus primarily on safety, testing whether a new treatment is safe enough to use in humans and determining appropriate dosages. Phase II trials begin to evaluate whether the treatment actually works to improve the disease, looking at clinical parameters and symptoms while continuing to monitor safety. Phase III trials compare the new treatment directly against standard treatments to determine whether it offers superior benefits. These trials are conducted at specialized medical centers in various countries including the United States, Europe, and other regions, with patient eligibility determined by factors such as disease stage, age, and specific characteristics of their condition.^[9]

Researchers continue to investigate additional neuroprotective strategies aimed at preserving nerve cell function and preventing further damage. These experimental approaches include various molecules designed to support cellular health, protect the myelin sheath, reduce inflammation in the nervous system, or address other aspects of disease pathology. While many of these therapies show promise in laboratory settings, translating these findings into effective treatments for patients requires extensive testing and validation through clinical trials.^[13]

Most common treatment methods

• Hormone replacement therapy
  • Lifesaving treatment for adrenal insufficiency using steroids to replace hormones the adrenal glands cannot produce
  • Must be taken for life with dosage adjustments during illness or stress
  • Prevents life-threatening adrenal crises in all patients with adrenoleukodystrophy
• Stem cell transplantation
  • Allogeneic hematopoietic stem cell transplantation using bone marrow or umbilical cord blood from donors
  • Only approved treatment that can stabilize progression of childhood cerebral adrenoleukodystrophy
  • Most effective when performed early with Loes score below 9 before significant symptoms develop
  • Carries risks including 8-12% transplant-related mortality, graft failure, and graft-versus-host disease
  • Requires eliminating the patient’s immune system with chemotherapy or radiation before transplant
• Gene therapy
  • Experimental treatment now approved as SKYSONA for early cerebral adrenoleukodystrophy
  • Uses patient’s own stem cells modified to include functioning ABCD1 gene
  • Eliminates risk of graft-versus-host disease since it uses patient’s own cells
  • Has shown ability to halt disease progression when given during early cerebral involvement
  • Long-term follow-up shows some patients remain stable years after treatment
• Lorenzo’s oil
  • Dietary therapy combining fatty acids from olive oil and rapeseed oil
  • Reduces very-long-chain fatty acids in the bloodstream
  • May prevent or delay symptom onset in boys diagnosed before brain involvement develops
  • Not effective in treating active cerebral disease or reversing existing symptoms
  • Does not prevent or treat adrenal insufficiency
• Supportive care
  • Physical therapy to maintain mobility and manage muscle stiffness
  • Medications for pain control in patients with spinal cord involvement
  • Assistance with bladder and bowel management as symptoms progress
  • Behavioral therapy and communication support for children with neurological symptoms
  • Psychological counseling for patients and families coping with the diagnosis